A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Clinical trial NCT04482309 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04482309
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Start date: 2020-08-18
Primary completion: 2027-03-23
Enrollment: 477

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.